BMC Immunology2014ResearchNon-viral Gene Delivery
Kyung Hee Noh, Yeong Min Park, Hyuk Soon Kim, Tae Heung Kang, Kwon‐ho Song, Young‐ho Lee, Yeongseon Byeon, Hat Nim Jeon, In Duk Jung, Byung Cheol Shin, Kyung‐mi Lee, Seung‐yong Seong, Hee Dong Han, Tae Woo Kim
Conventional adjuvants such as Complete Freund’s Adjuvant (CFA) and Incomplete Freund’s Adjuvant (IFA) are potent but toxic, limiting clinical use. A safer, biodegradable adjuvant system was needed to enhance antigen-specific humoral and cellular immunity without severe local or systemic side effects. Safety: CH-HG…
Read the article →Bioconjugate Chemistry2014ResearchNon-viral Gene Delivery
Hauptmann N, Pion M, Wehner R, Muñoz-Fernández M-A, Schmitz M, Voit B, Appelhans D
Dendritic cell (DC)-based immunotherapy requires efficient delivery of antigens to immature DCs (iDCs) and maintenance of their immunostimulatory and migratory functions. Cationic PEI carriers are limited by dose-dependent toxicity and aggregation at endosomal pH, so a biocompatible, pH-responsive carrier is needed…
Read the article →Pharmaceutical Development and Technology (Informa Healthcare)2014ResearchNon-viral Gene Delivery
Jaber Emami, Aida Pourmashhadi, Hojat Sadeghi, Jaleh Varshosaz, Hamed Hamishehkar
COX-2 is overexpressed in non-small cell lung cancer (NSCLC) and is associated with poor prognosis. Celecoxib (Cxb), a COX-2 inhibitor, has antiproliferative and proapoptotic effects, but systemic administration carries cardiovascular risks. Pulmonary inhalation delivery of Cxb encapsulated in biodegradable PLGA…
Read the article →2014ReviewNon-viral Gene Delivery
Singh Ms, Bhaskar S.
Cancer immunotherapy can induce specific antitumor immunity, control metastases, and provide immunological memory, but faces barriers including immunosuppressive tumour microenvironments and poor delivery of immunomodulators. Nanocarriers offer a versatile way to deliver antigens, adjuvants, cytokines, antibodies…
Read the article →European Journal of Pharmaceutics and Biopharmaceutics.2014ReviewNon-viral Gene Delivery
Slavomíra Doktorovová, Eliana B. Souto, Amélia Maria Silva
Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) were developed as alternative colloidal carriers with better stability and tolerability than polymeric nanoparticles. However, in vitro toxicity data were scattered across many cell lines, assays, exposure times, concentrations, and formulations…
Read the article →PLOS ONE2013ResearchNon-viral Gene Delivery
Lais Chayabam, Aline Laino Sodre, Bruno A. Curzio, Martin H. Bonamino
Genetic modification of T lymphocytes is essential for both basic research and immunotherapy (e.g., CAR-T cell generation), but existing methods rely on expensive commercial electroporation kits (Lonza Nucleofector® kits) or time-consuming viral vector production. The high cost and dependence on proprietary reagents…
Read the article →Biochimica et Biophysica Acta (BBA) - Biomembranes2013ResearchNon-viral Gene Delivery
Fatemeh Madani, Rania Abdo, Staffan Lindberg, Hisaaki Hirose, Shiroh Futaki, Ulo Langel, Astrid Gräslund
Cell-penetrating peptides (CPPs) can internalise cells with biologically active cargo, but endosomal entrapment is a major limitation for cytoplasmic delivery, as cargo molecules must escape the endosome before degradation and acidification. While CPPs are known to enter cells via endocytosis, the background…
Read the article →The Journal of Immunology2013ResearchNon-viral Gene Delivery
Ying-Chun Lo, Michael A. Edidin, Jonathan D. Powell
Soluble anti-CD3 antibodies are potent T cell mitogens but activate all T cells regardless of TCR specificity, limiting their therapeutic utility for boosting antigen-specific responses. TCRs cluster into microclusters on the surface of antigen-experienced T cells but remain dispersed on naive T cells. This…
Read the article →Drug Discovery Today.2013ReviewDrug Delivery
Gan L, Wang J, Jiang M, Bartlett H, Ouyang D, Eperjesi F, Liu J, Gan Y
Topical ocular drug delivery is limited by tear turnover, corneal and conjunctival barriers, efflux transporters, and poor water solubility of many drug candidates. Lipid-based nanocarriers may improve ocular bioavailability, prolong preocular residence, enhance corneal penetration, and provide controlled release…
Read the article →Journal of Controlled Release2013ReviewNon-viral Gene Delivery
Ragelle, H.; Vandermeulen, G.; Préat, V
Chitosan is attractive for siRNA delivery because it is cationic, biocompatible, biodegradable, mucoadhesive, and permeation-enhancing. However, native chitosan suffers from low solubility at physiological pH, poor buffering capacity, instability in biological fluids, and insufficient endosomal escape, limiting…
Read the article →Biomedical Materials* (*Biomed. Mater.*)2012ReviewNon-viral Gene Delivery
Not Fully Listed In The Supplied File; Corresponding Authors Are Isaac Ojea ([email protected]) And Victor Puntes ([email protected])
Viral vectors give high gene-transfer efficiency but carry risks of immunogenicity, oncogenic transformation, limited cargo capacity, and manufacturing difficulty. Nonviral nanocarriers are safer and cheaper alternatives, but they still suffer from low transfection efficiency because of extracellular and…
Read the article →PNAS2012ResearchNon-viral Gene Delivery
David N. Nguyen, Kerry P. Mahon, Ghania Chikh, Phillip Kim, Hattie Chung, Alain P. Vicari, Kevin T. Love, Michael Goldberg, Steve Chen, Arthur M. Krieg, Jianzhu Chen, Robert Langer, Daniel G. Anderson
TLR7/8 agonists are promising vaccine adjuvants and antivirals, but RNA agonists are unstable and small-molecule agonists cause systemic toxicity. A delivery system specifically designed to deliver immunostimulatory RNA (isRNA) to TLR-expressing cells could enable safer and more localised innate immune activation. 14…
Read the article →Journal of Controlled Release2012ResearchNon-viral Gene Delivery
Hughes Ad, King Mr
Metastasis is the leading cause of cancer mortality, and circulating tumour cells (CTCs) are key to metastatic spread. Doxorubicin (DXR) is effective but systemically toxic and nonspecific. A targeted delivery system was needed to capture and kill CTCs under physiologically relevant flow while reducing off-target…
Read the article →Current Opinion in Lipidology2012ReviewNon-viral Gene Delivery
Vickers Kc, Remaley At
Extracellular miRNAs are unusually stable in plasma and their circulating levels change with disease, making them promising biomarkers. They are associated with lipid-based carriers—exosomes, microvesicles, apoptotic bodies, and lipoproteins—as well as lipid-free proteins. Whether these carriers mediate functional…
Read the article →African Journal of Biotechnology2011ResearchNon-viral Gene Delivery
Wang B, Zhou J, Cui S, Yang B, Zhao Y, Zhao B, Duan Y, Zhang S
Although cationic liposomes are widely used non-viral gene vectors, the structure–activity relationships governing their transfection efficiency remain poorly understood, and optimisation is still largely trial-and-error. A systematic in vitro study was needed to correlate lipoplex physicochemical properties and…
Read the article →Biomacromolecules2011ResearchNon-viral Gene Delivery
Joel C. Sunshine, Marib I. Akanda, David Li, Kristen L. Kozielski, Jordan J. Green
Non-viral gene delivery needs safer and more effective polymeric vectors. Poly(β-amino ester)s (PBAEs) are promising, but previous studies had not systematically modified all three structural elements—backbone, side chain, and end group—within one library to analyse how small structural changes affect transfection…
Read the article →Nanomedicine: Nanotechnology, Biology, and Medicine2011ResearchNon-viral Gene Delivery
Shashi Prasad, Virginia Cody, Jennifer K. Saucier-Sawyer, W. Mark Saltzman, Clarence T. Sasaki, Richard L. Edelson, Martin A. Birchall, Douglas J. Hanlon
Efficient antigen delivery remains a major challenge for dendritic cell (DC)-based immunotherapy of solid-organ malignancies. Soluble tumour lysates suffer from instability, poor DC internalisation, and inefficient cross-presentation to cytotoxic T lymphocytes. PLGA nanoparticles may protect antigens, improve…
Read the article →Journal of Controlled Release2011ResearchNon-viral Gene Delivery
Wong Sp, Argyros O, Howe Sj, Harbottle Rp
Nonviral vectors have rarely been tested in neonatal mice because of poor delivery efficiency, yet early gene therapy could prevent irreversible disease, requires lower vector doses due to small body size, and may avoid immune reactions before immune maturation. Viral vectors carry risks such as insertional…
Read the article →2011ReviewDrug Delivery
Torchilin Vp
Lipid-based nanocarriers such as liposomes and micelles can protect drugs, reduce nonspecific toxicity, and improve pharmacokinetics, but conventional formulations are limited by rapid clearance, poor targeting, and inefficient intracellular delivery. Engineering “multifunctional pharmaceutical nanocarriers” that…
Read the article →Proceedings of the National Academy of Sciences of the United States of America2010ResearchNon-viral Gene Delivery
Kevin T. Love, Kerry P. Mahon, Christopher G. Levins, Kathryn A. Whitehead, William Querbes, J. Robert Dorkin, June Qin, William Cantley, Liu Liang Qin, Timothy Racie, Maria Frank-Kamenetsky, Ka Ning Yip, Rene Alvarez, Dinah W. Y. Sah, Antonin De Fougerolles, Kevin Fitzgerald, Victor Koteliansky, Ak
Existing siRNA delivery systems required high doses (1 mg/kg) for hepatic gene silencing. A more potent, well-tolerated lipid-like delivery material was needed to enable low-dose RNAi therapeutics and multi-gene silencing in vivo. C12-200 enabled Factor VII silencing at doses below 0.01 mg/kg in mice, 100-fold more…
Read the article →Journal of Controlled Release2010ResearchNon-viral Gene Delivery
IL-12 gene therapy is attractive for cancer because local IL-12 expression can prime anti-tumour immunity while reducing systemic toxicity. However, non-viral gene delivery to tumours is inefficient, and simple sonoporation using ultrasound alone does not achieve sufficient cancer gene therapy. The authors tested…
Read the article →International Journal of Pharmaceutics2010ResearchNon-viral Gene Delivery
Zhang Y, Li H, Sun J, Gao J, Liu W, Li B, Guo Y, Chen J
DC-Chol/DOPE cationic liposomes are efficient non-viral vectors, but the effects of DC-Chol/DOPE molar ratio, PEGylation, and serum on pDNA versus siRNA delivery were unclear. The study also aimed to test whether pDNA and siRNA have different transfection mechanisms in these liposomes. Optimal DC-Chol/DOPE molar…
Read the article →Clinical & Experimental Metastasis2010ResearchNon-viral Gene Delivery
Seo Sh, Han Hd, Noh Kh, Kim Tw, Son Sw
Chemo-immunotherapy combinations are limited by systemic immunotoxicity from cancer drugs and rapid clearance of low-molecular-weight drugs after intratumoral injection. A local, biodegradable delivery system was needed to sustain drug/GMCSF exposure at the tumour site, reduce systemic toxicity, and promote tumour…
Read the article →Clinical Cancer Research2010ResearchNon-viral Gene Delivery
Han Hd, Mangala Ls, Lee Jw, Shahzad Mmk, Kim Hs, Shen D, Nam Ej, Mora Em, Stone Rl, Lu C, Lee Sj, Roh Jw, Nick Am, Lopez-Berestein G, Sood Ak
siRNA has therapeutic potential, but in vivo delivery is limited by rapid clearance, nuclease degradation, and nonspecific distribution. A tumour-targeted, biocompatible delivery system was needed to increase intratumoral siRNA accumulation, reduce off-target effects, and enable silencing of growth-promoting genes in…
Read the article →